在造血干细胞移植（HSCT）中，维生素D缺乏状况与并发症的增加有时存在关联，主要是移植物抗宿主病（GvHD），对生存率可能产生影响。然而，来自各种研究的结果并不一致。本分析旨在研究围手术期维生素D水平对接受人类白血病抗原（HLA）相配（相关/无关）HSCT的急性白血病（AL）患者的移植结果的影响。本研究是一项单中心回顾性研究。纳入了2008年至2019年间接受完全配型或9/10配型（相关/无关）HSCT的AL患者，包括急性淋巴细胞白血病（ALL）、急性髓系白血病（AML）或混合表型急性白血病（MPAL）。维生素D缺乏被定义为血清25-羟基维生素D3水平<20ng/mL。缺乏的患者接受口服维生素D补充，每周剂量为60,000IU，连续8周，然后以每天800IU的维生素D维持剂量。在补充开始后的4个月内重复测定维生素D水平。接受纠正的患者，重复结果> 20ng/mL被认为达到充分水平。根据围手术期内（移植后120天内）的维生素D水平，将患者分为维生素D充分组（> 20ng/mL）和维生素D缺乏组（≤ 20ng/mL）。将围手术期维生素D状况与移植结果相关联。共纳入了133名患者，其中31名缺乏（中位数维生素D水平15.0ng/mL），102名充分（中位数维生素D水平34ng/mL）在移植时。两组在年龄、诊断、欧洲骨髓移植协会（EBMT）评分和疾病风险指数（DRI）方面均匹配。两组在中性粒细胞或血小板移植成功时间、巨细胞病毒（CMV）再激活、急性移植物抗宿主病（aGVHD）或慢性移植物抗宿主病（cGVHD）方面没有差异。复发率、无进展生存期（PFS）和总生存期（OS）在两组之间也相当。我们患者队列中维生素D缺乏的发生率较高。在移植时缺乏维生素D的患者并没有表现出劣质结果，这表明维生素D在影响移植结果方面起到的作用有限。 版权所有©2023。由Elsevier B.V.出版。

In hematopoietic stem cell transplant (HSCT), vitamin D deficiency has been variably associated with increased complications, primarily graft versus host disease (GvHD), with a potential impact on survival. Results from various studies however, have not been consistent. This analysis was conducted to study the impact of peri-transplant vitamin D levels on transplant outcomes in patients with acute leukemia (AL) who underwent HLA matched (related/unrelated) HSCT.This was a single center retrospective study. Patients of AL including Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) or Mixed Phenotypic Acute Leukemia (MPAL) who underwent fully matched or 9/10 transplants (related/unrelated) between 2008 and 2019 were included. Vitamin D deficiency was defined as serum 25-hydroxy vitamin D3 levels <20 ng/mL. Those with deficiency received replacement with oral vitamin D at a dose of 60,000 IU weekly for 8 weeks followed by maintenance with daily vitamin D (800 IU/day). Vitamin D levels were repeated at 4 months from start of replacement. For patients who received correction, repeat levels >20 ng/ml were considered replete. Based on vitamin D levels in the peri-transplant period (within 120 days of transplant), patients were categorised as either vitamin D replete (> 20 ng/ml) or deplete (≤ 20 ng/ml). Peri-transplant vitamin D status was correlated with transplant outcomes.Of the 133 patients included, 31 were deplete (median vitamin D 15.0 ng/ml) and 102 were replete (median vitamin D 34 ng/ml) at time of transplant. Both groups were matched for age, diagnosis, EBMT score and disease risk index (DRI). There were no differences in time to neutrophil or platelet engraftment, CMV reactivation, acute GVHD (aGVHD) or chronic GVHD (cGVHD) between the two groups. Relapse rate, Progression Free Survival (PFS) and Overall Survival (OS) were also comparable between the 2 groups.The incidence of vitamin D deficiency was high in our patient cohort. Patients who were vitamin D deficient at the time of transplant did not have inferior outcomes, suggesting a limited role of vitamin D in influencing transplant outcomes.Copyright © 2023. Published by Elsevier B.V.